Pharvaris N.V.
PHVSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Pharvaris N.V. (PHVS) is listed under Biotechnology. The $2.66B market capitalization puts PHVS squarely in mid-cap range for its industry. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.
Market Cap
$2.66B
Beta
-2.32
P/E (TTM)
—
P/E (Fwd)
-12.22
EPS (TTM)
$-3.01
EPS (Fwd)
$-3.10
ROE
-70.5%
ROA
-42.3%
Cash
$318.3M
Total Debt
$673,728
Free CF
-$90.4M
52W Change
47.2%
Annual Financials
Cash vs Debt
Where PHVS stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, PHVS finished 14.75% above its 150-day moving average ($30.65) and 19.54% above its 200-day moving average ($29.42). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PHVS overbought or oversold?
At the September 3, 2026 close, PHVS's RSI(14) was 58.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $318.3M in cash and $674K in debt, PHVS maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$90.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -70.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The relatively low beta of -2.32 suggests PHVS is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing PHVS.